NO320099B1 - 3-fenylpyridinderivater,fremgangsmate for fremstilling og anvendelse derav, samt medikament. - Google Patents

3-fenylpyridinderivater,fremgangsmate for fremstilling og anvendelse derav, samt medikament. Download PDF

Info

Publication number: NO320099B1
Authority: NO; Norway
Prior art keywords: formula; compound; methyl; trifluoromethyl; phenyl
Prior art date: 1999-02-24

Application number

NO20014098A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014098L (no

NO20014098D0 (no

Inventor

Heinz Stadler

Walter Hunkeler

Thierry Godel

Michael Bos

Torsten Hoffmann

Patrick Schnider

Guido Galley

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-24

Filing date

2001-08-23

Publication date

2005-10-24

2001-08-23 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2001-08-23 Publication of NO20014098L publication Critical patent/NO20014098L/no

2001-08-23 Publication of NO20014098D0 publication Critical patent/NO20014098D0/no

2005-10-24 Publication of NO320099B1 publication Critical patent/NO320099B1/no

Links

238000000034 method Methods 0.000 title claims description 26
238000002360 preparation method Methods 0.000 title claims description 18
239000003814 drug Substances 0.000 title claims description 9
229940079593 drug Drugs 0.000 title claims description 6
150000005361 3-phenylpyridines Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 112
150000003839 salts Chemical class 0.000 claims description 16
238000006243 chemical reaction Methods 0.000 claims description 15
125000001424 substituent group Chemical group 0.000 claims description 12
239000000654 additive Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
102000002002 Neurokinin-1 Receptors Human genes 0.000 claims description 5
108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 5
230000009467 reduction Effects 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
229940044551 receptor antagonist Drugs 0.000 claims description 4
239000002464 receptor antagonist Substances 0.000 claims description 4
WRKCFWQULJFVBO-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[3-(2-methylphenyl)pyridin-4-yl]propanamide Chemical group C=1C=NC=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WRKCFWQULJFVBO-UHFFFAOYSA-N 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
SFMWMKZRUGYFBA-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-(3-naphthalen-1-ylpyridin-4-yl)propanamide Chemical compound C=1C=NC=C(C=2C3=CC=CC=C3C=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SFMWMKZRUGYFBA-UHFFFAOYSA-N 0.000 claims description 2
DMOOMKYJDBINDF-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[3-(4-fluoro-2-methylphenyl)pyridin-4-yl]-n,2-dimethylpropanamide Chemical compound C=1C=NC=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DMOOMKYJDBINDF-UHFFFAOYSA-N 0.000 claims description 2
229940047889 isobutyramide Drugs 0.000 claims description 2
230000004048 modification Effects 0.000 claims description 2
238000012986 modification Methods 0.000 claims description 2
QOQSAUOBLCCCRM-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-5-(2-methoxyphenyl)-n-methyl-2-(4-methylpiperazin-1-yl)pyridine-4-carboxamide Chemical compound COC1=CC=CC=C1C1=CN=C(N2CCN(C)CC2)C=C1C(=O)N(C)CC1=CC(Cl)=CC(Cl)=C1 QOQSAUOBLCCCRM-UHFFFAOYSA-N 0.000 claims description 2
HJBXFIIMRLNJEP-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(2-methoxyphenyl)-n-methyl-2-(4-methylpiperazin-1-yl)pyridine-4-carboxamide Chemical compound COC1=CC=CC=C1C1=CN=C(N2CCN(C)CC2)C=C1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HJBXFIIMRLNJEP-UHFFFAOYSA-N 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims 6
239000001257 hydrogen Substances 0.000 claims 6
125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
201000010099 disease Diseases 0.000 claims 2
150000002431 hydrogen Chemical class 0.000 claims 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
IHTFHQQTYOIZOZ-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(2-chlorophenyl)-n-methylpyridine-4-carboxamide Chemical compound C=1C=NC=C(C=2C(=CC=CC=2)Cl)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IHTFHQQTYOIZOZ-UHFFFAOYSA-N 0.000 claims 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
239000000243 solution Substances 0.000 description 45
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
239000013078 crystal Substances 0.000 description 14
238000003756 stirring Methods 0.000 description 14
238000004587 chromatography analysis Methods 0.000 description 13
229910052943 magnesium sulfate Inorganic materials 0.000 description 13
235000019341 magnesium sulphate Nutrition 0.000 description 13
102100024304 Protachykinin-1 Human genes 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000012267 brine Substances 0.000 description 12
239000000203 mixture Substances 0.000 description 12
239000012044 organic layer Substances 0.000 description 12
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 10
101800003906 Substance P Proteins 0.000 description 10
239000000725 suspension Substances 0.000 description 10
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 9
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
239000003921 oil Substances 0.000 description 8
235000019198 oils Nutrition 0.000 description 8
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 8
239000002904 solvent Substances 0.000 description 8
RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
239000012230 colorless oil Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000829 suppository Substances 0.000 description 5
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
229910052786 argon Inorganic materials 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
238000001816 cooling Methods 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 3
ATLQGZVLWOURFU-UHFFFAOYSA-N 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(CBr)=CC(C(F)(F)F)=C1 ATLQGZVLWOURFU-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008298 dragée Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
239000001993 wax Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
CTJIGYSODYOMGI-UHFFFAOYSA-N 1-(bromomethyl)-3,5-dichlorobenzene Chemical compound ClC1=CC(Cl)=CC(CBr)=C1 CTJIGYSODYOMGI-UHFFFAOYSA-N 0.000 description 2
SFEVQUPISPQHOG-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl chloride Chemical compound ClC(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SFEVQUPISPQHOG-UHFFFAOYSA-N 0.000 description 2
LVPSLWDFHJYOBL-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[3-[2-(trifluoromethyl)phenyl]pyridin-4-yl]propanamide Chemical compound C=1C=NC=C(C=2C(=CC=CC=2)C(F)(F)F)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LVPSLWDFHJYOBL-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 description 2
KDCSJERZLIJPLK-UHFFFAOYSA-N 3-(2-methylphenyl)pyridine-4-carboxylic acid Chemical compound CC1=CC=CC=C1C1=CN=CC=C1C(O)=O KDCSJERZLIJPLK-UHFFFAOYSA-N 0.000 description 2
DCVBGEPDEACJOB-UHFFFAOYSA-N 3-iodo-n-methylpyridine-4-carboxamide Chemical compound CNC(=O)C1=CC=NC=C1I DCVBGEPDEACJOB-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102000003141 Tachykinin Human genes 0.000 description 2
102000007124 Tachykinin Receptors Human genes 0.000 description 2
108010072901 Tachykinin Receptors Proteins 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000005595 deprotonation Effects 0.000 description 2
238000010537 deprotonation reaction Methods 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
239000003925 fat Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000006260 foam Substances 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
-1 invert sugar Substances 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
SCPYZUAEPUWQKQ-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-methyl-3-(2-methylphenyl)pyridine-4-carboxamide Chemical compound C=1C=NC=C(C=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SCPYZUAEPUWQKQ-UHFFFAOYSA-N 0.000 description 2
239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
108060008037 tachykinin Proteins 0.000 description 2
239000002462 tachykinin receptor antagonist Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
VBLKGQOKUPVXSS-UHFFFAOYSA-N (3-bromopyridin-2-yl)methanamine Chemical compound NCC1=NC=CC=C1Br VBLKGQOKUPVXSS-UHFFFAOYSA-N 0.000 description 1
IQMLIVUHMSIOQP-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)boronic acid Chemical compound CC1=CC(F)=CC=C1B(O)O IQMLIVUHMSIOQP-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
DCHZONUXTLCVPP-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[3-(2-methylphenyl)pyridin-4-yl]propanamide;hydrochloride Chemical compound Cl.C=1C=NC=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DCHZONUXTLCVPP-UHFFFAOYSA-N 0.000 description 1
XXOVRNJWJNFQSM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[3-(2-chlorophenyl)pyridin-4-yl]-n,2-dimethylpropanamide Chemical compound C=1C=NC=C(C=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XXOVRNJWJNFQSM-UHFFFAOYSA-N 0.000 description 1
HOPFIHKIAPSDNC-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[3-(2-fluorophenyl)pyridin-4-yl]-n,2-dimethylpropanamide;hydrochloride Chemical compound Cl.C=1C=NC=C(C=2C(=CC=CC=2)F)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HOPFIHKIAPSDNC-UHFFFAOYSA-N 0.000 description 1
BTKNEPOTETXVAE-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[3-(2-methoxyphenyl)pyridin-4-yl]-n,2-dimethylpropanamide Chemical compound COC1=CC=CC=C1C1=CN=CC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BTKNEPOTETXVAE-UHFFFAOYSA-N 0.000 description 1
LSEKWLUXMJBLLK-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[3-(2-methoxyphenyl)pyridin-4-yl]-n,2-dimethylpropanamide;hydrochloride Chemical compound Cl.COC1=CC=CC=C1C1=CN=CC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LSEKWLUXMJBLLK-UHFFFAOYSA-N 0.000 description 1
DCRYNENGYRFZJO-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[3-(4-fluoro-2-methylphenyl)pyridin-4-yl]-n,2-dimethylpropanamide;hydrochloride Chemical compound Cl.C=1C=NC=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DCRYNENGYRFZJO-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
MJSNRTLYWDXHAQ-UHFFFAOYSA-N 3-iodopyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1I MJSNRTLYWDXHAQ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
WTQHWDQVTYBEGD-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methoxymethyl]-3-(2-methylphenyl)pyridine Chemical compound CC1=CC=CC=C1C1=CN=CC=C1COCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WTQHWDQVTYBEGD-UHFFFAOYSA-N 0.000 description 1
PKYLPZVBYCQPIL-UHFFFAOYSA-N 5-(2-chlorophenyl)-n-methyl-2-(4-methylpiperazin-1-yl)pyridine-4-carboxamide Chemical compound CNC(=O)C1=CC(N2CCN(C)CC2)=NC=C1C1=CC=CC=C1Cl PKYLPZVBYCQPIL-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010011971 Decreased interest Diseases 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 description 1
102000028517 Neuropeptide receptor Human genes 0.000 description 1
108070000018 Neuropeptide receptor Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000012545 Psychophysiologic disease Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 1
DHVHORCFFOSRBP-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DHVHORCFFOSRBP-UHFFFAOYSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000036427 bronchial hyperreactivity Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
HGMRXLZVAAVHGD-UHFFFAOYSA-N ethyl 2-(4-methylpiperazin-1-yl)pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(N2CCN(C)CC2)=C1 HGMRXLZVAAVHGD-UHFFFAOYSA-N 0.000 description 1
IGRLNCOFYMWKBU-UHFFFAOYSA-N ethyl 2-chloropyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(Cl)=C1 IGRLNCOFYMWKBU-UHFFFAOYSA-N 0.000 description 1
NQTIWJACRWXYCQ-UHFFFAOYSA-N ethyl 5-bromo-2-(4-methylpiperazin-1-yl)pyridine-4-carboxylate Chemical compound C1=C(Br)C(C(=O)OCC)=CC(N2CCN(C)CC2)=N1 NQTIWJACRWXYCQ-UHFFFAOYSA-N 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 description 1
KHGOKLNKGKNYAA-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[3-(2-methylphenyl)pyridin-4-yl]methanamine;hydrochloride Chemical compound Cl.CC1=CC=CC=C1C1=CN=CC=C1CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KHGOKLNKGKNYAA-UHFFFAOYSA-N 0.000 description 1
UVZDGIBBNJBLHT-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(2-chlorophenyl)-n-methylpyridine-4-carboxamide;hydrochloride Chemical compound Cl.C=1C=NC=C(C=2C(=CC=CC=2)Cl)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UVZDGIBBNJBLHT-UHFFFAOYSA-N 0.000 description 1
YPMWNBHKBBWPSF-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(2-methylphenyl)pyridine-4-carboxamide Chemical compound CC1=CC=CC=C1C1=CN=CC=C1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YPMWNBHKBBWPSF-UHFFFAOYSA-N 0.000 description 1
KEIMCAPEIBJVLW-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-methyl-2-(4-methylpiperazin-1-yl)-5-phenylpyridine-4-carboxamide Chemical compound C=1C(N2CCN(C)CC2)=NC=C(C=2C=CC=CC=2)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KEIMCAPEIBJVLW-UHFFFAOYSA-N 0.000 description 1
ZPNDZCLPUGCZSL-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-methyl-3-(2-methylphenyl)pyridine-4-carboxamide;hydrochloride Chemical compound Cl.C=1C=NC=C(C=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZPNDZCLPUGCZSL-UHFFFAOYSA-N 0.000 description 1
FFVZOVSQIUBVSK-UHFFFAOYSA-N n-methyl-2-(2-methylphenyl)pyridin-4-amine Chemical compound CNC1=CC=NC(C=2C(=CC=CC=2)C)=C1 FFVZOVSQIUBVSK-UHFFFAOYSA-N 0.000 description 1
NOJXJHPLCSJPIO-UHFFFAOYSA-N n-methyl-3-(2-methylphenyl)pyridine-4-carboxamide Chemical compound CNC(=O)C1=CC=NC=C1C1=CC=CC=C1C NOJXJHPLCSJPIO-UHFFFAOYSA-N 0.000 description 1
PLWAKFARFCNHJO-UHFFFAOYSA-N n-methylpyridine-4-carboxamide Chemical compound CNC(=O)C1=CC=NC=C1 PLWAKFARFCNHJO-UHFFFAOYSA-N 0.000 description 1
HUMMCEUVDBVXTQ-UHFFFAOYSA-N naphthalen-1-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=CC2=C1 HUMMCEUVDBVXTQ-UHFFFAOYSA-N 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
108010072906 phosphoramidon Proteins 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000002466 tachykinin receptor agonist Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
230000007306 turnover Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20014098A 1999-02-24 2001-08-23 3-fenylpyridinderivater,fremgangsmate for fremstilling og anvendelse derav, samt medikament. NO320099B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99103503		1999-02-24
PCT/EP2000/001223 WO2000050401A1 (en)	1999-02-24	2000-02-15	3-phenylpyridine derivatives and their use as nk-1 receptor antagonists

Publications (3)

Publication Number	Publication Date
NO20014098L NO20014098L (no)	2001-08-23
NO20014098D0 NO20014098D0 (no)	2001-08-23
NO320099B1 true NO320099B1 (no)	2005-10-24

Family

ID=8237624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014098A NO320099B1 (no)	1999-02-24	2001-08-23	3-fenylpyridinderivater,fremgangsmate for fremstilling og anvendelse derav, samt medikament.

Country Status (33)

Country	Link
US (1)	US6225316B1 (da)
EP (1)	EP1157005B1 (da)
JP (1)	JP4068305B2 (da)
KR (1)	KR100437587B1 (da)
CN (1)	CN1134417C (da)
AR (1)	AR029616A1 (da)
AT (1)	ATE280158T1 (da)
AU (1)	AU772446B2 (da)
BR (1)	BR0008494A (da)
CA (1)	CA2364662C (da)
CO (1)	CO5140087A1 (da)
CZ (1)	CZ20013047A3 (da)
DE (1)	DE60015089T2 (da)
DK (1)	DK1157005T3 (da)
ES (1)	ES2230070T3 (da)
GC (1)	GC0000183A (da)
HK (1)	HK1044942B (da)
HR (1)	HRP20010604A2 (da)
HU (1)	HUP0200139A3 (da)
IL (2)	IL144851A0 (da)
JO (1)	JO2254B1 (da)
MA (1)	MA26773A1 (da)
MY (1)	MY122630A (da)
NO (1)	NO320099B1 (da)
NZ (1)	NZ513370A (da)
PL (1)	PL350428A1 (da)
PT (1)	PT1157005E (da)
RU (1)	RU2236402C2 (da)
SI (1)	SI1157005T1 (da)
TR (1)	TR200102489T2 (da)
WO (1)	WO2000050401A1 (da)
YU (1)	YU59901A (da)
ZA (1)	ZA200106371B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9928222D0 (en)	1999-11-30	2000-01-26	Univ Sheffield	Chiral catalysts for asymmetric acylation and related transformations
AUPQ514600A0 (en)	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
CN1178917C (zh) *	2000-07-14	2004-12-08	弗·哈夫曼-拉罗切有限公司	作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en) *	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
SE0004245D0 (sv)	2000-11-20	2000-11-20	Pharmacia Ab	Novel compounds and their use
NZ525700A (en) *	2000-11-20	2004-12-24	Biovitrum Ab	Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US7176322B2 (en) *	2002-05-23	2007-02-13	Amgen Inc.	Calcium receptor modulating agents
US6908935B2 (en) *	2002-05-23	2005-06-21	Amgen Inc.	Calcium receptor modulating agents
JP2006508061A (ja) *	2002-09-20	2006-03-09	ファイザー・プロダクツ・インク	エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
NZ560232A (en)	2005-02-25	2010-11-26	Hoffmann La Roche	Tablets with improved drug substance dispersibility
EP2774925B1 (en)	2005-11-08	2016-12-28	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of ATP-binding cassette transporters
RU2419609C2 (ru) *	2005-11-30	2011-05-27	Зольвай Фармасьютиклз Гмбх	Новые антагонисты nk1 и nk2
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
TW200906408A (en) *	2007-04-24	2009-02-16	Takeda Pharmaceutical	Piperidine derivative and use thereof
WO2008141119A2 (en)	2007-05-09	2008-11-20	Vertex Pharmaceuticals Incorporated	Modulators of cftr
PL2231606T3 (pl)	2007-12-07	2013-07-31	Vertex Pharma	Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
HUE031913T2 (en)	2007-12-07	2017-08-28	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP5523352B2 (ja)	2008-02-28	2014-06-18	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
KR100943878B1 (ko) *	2008-07-11	2010-02-24	오토스테크 주식회사	디지털방식 눈부심 방지 장치 및 그 제어 방법
EP2350010B1 (en) *	2008-10-30	2014-03-26	Merck Sharp & Dohme Corp.	Isonicotinamide orexin receptor antagonists
ES2663351T3 (es) *	2009-11-17	2018-04-12	Novartis Ag	Derivados de aril-piridina como inhibidores de la aldosterona sintasa
RS62767B1 (sr)	2010-04-07	2022-01-31	Vertex Pharma	Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
US8410107B2 (en) *	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
MX355183B (es)	2012-01-25	2018-04-09	Vertex Pharma	Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
BR112016009811A2 (pt)	2013-11-08	2017-12-05	Kissei Pharmaceutical	derivado de carboximetil piperidina
HRP20210516T2 (hr)	2013-11-12	2021-10-01	Vertex Pharmaceuticals Incorporated	Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
KR102576006B1 (ko)	2014-11-18	2023-09-06	버텍스 파마슈티칼스 인코포레이티드	고처리량 시험 고성능 액체 크로마토그래피의 수행 방법
EA201891472A1 (ru)	2015-12-22	2018-12-28	Такеда Фармасьютикал Компани Лимитед	Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
CN115915941B (zh)	2020-05-06	2025-07-15	拜耳公司	作为杀真菌化合物的吡啶（硫代）酰胺
BR112022024405A2 (pt)	2020-06-04	2023-01-31	Bayer Ag	Heterociclil piridinas como novos fungicidas
EP4441049A1 (en)	2021-11-30	2024-10-09	Bayer Aktiengesellschaft	Bis(hetero)aryl thioether oxadiazines as fungicidal compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4174209A (en) *	1978-06-19	1979-11-13	Eli Lilly And Company	Herbicidal 1-alkyl-3-phenylpyridinium salts
US4745123A (en) *	1986-02-18	1988-05-17	Warner-Lambert Company	Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
JPH0794439B2 (ja) *	1990-05-31	1995-10-11	フアイザー・インコーポレイテツド	置換ピペリジンの製造法
IL111960A (en)	1993-12-17	1999-12-22	Merck & Co Inc	Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69434063D1 (de)	1993-12-29	2004-11-11	Merck Sharp & Dohme	Substituierte Morpholinderivate und ihre Verwendung als therapeutische Mittel
IL112778A0 (en)	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW394773B (en) *	1995-03-24	2000-06-21	Takeda Chemical Industries Ltd	Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
US5972938A (en)	1997-12-01	1999-10-26	Merck & Co., Inc.	Method for treating or preventing psychoimmunological disorders

2000
- 2000-02-15 EP EP00909174A patent/EP1157005B1/en not_active Expired - Lifetime
- 2000-02-15 SI SI200030546T patent/SI1157005T1/xx unknown
- 2000-02-15 AT AT00909174T patent/ATE280158T1/de not_active IP Right Cessation
- 2000-02-15 TR TR2001/02489T patent/TR200102489T2/xx unknown
- 2000-02-15 DK DK00909174T patent/DK1157005T3/da active
- 2000-02-15 NZ NZ513370A patent/NZ513370A/xx unknown
- 2000-02-15 WO PCT/EP2000/001223 patent/WO2000050401A1/en not_active Ceased
- 2000-02-15 CZ CZ20013047A patent/CZ20013047A3/cs unknown
- 2000-02-15 CN CNB008042322A patent/CN1134417C/zh not_active Expired - Fee Related
- 2000-02-15 AU AU31549/00A patent/AU772446B2/en not_active Ceased
- 2000-02-15 CA CA002364662A patent/CA2364662C/en not_active Expired - Fee Related
- 2000-02-15 JP JP2000600984A patent/JP4068305B2/ja not_active Expired - Fee Related
- 2000-02-15 PL PL00350428A patent/PL350428A1/xx not_active Application Discontinuation
- 2000-02-15 KR KR10-2001-7010731A patent/KR100437587B1/ko not_active Expired - Fee Related
- 2000-02-15 ES ES00909174T patent/ES2230070T3/es not_active Expired - Lifetime
- 2000-02-15 YU YU59901A patent/YU59901A/sh unknown
- 2000-02-15 HR HR20010604A patent/HRP20010604A2/hr not_active Application Discontinuation
- 2000-02-15 DE DE60015089T patent/DE60015089T2/de not_active Expired - Lifetime
- 2000-02-15 HK HK02106317.1A patent/HK1044942B/zh not_active IP Right Cessation
- 2000-02-15 BR BR0008494-8A patent/BR0008494A/pt not_active Application Discontinuation
- 2000-02-15 RU RU2001125893/04A patent/RU2236402C2/ru not_active IP Right Cessation
- 2000-02-15 HU HU0200139A patent/HUP0200139A3/hu unknown
- 2000-02-15 PT PT00909174T patent/PT1157005E/pt unknown
- 2000-02-15 IL IL14485100A patent/IL144851A0/xx active IP Right Grant
- 2000-02-16 US US09/505,359 patent/US6225316B1/en not_active Expired - Fee Related
- 2000-02-22 JO JO200015A patent/JO2254B1/en active
- 2000-02-22 CO CO00012321A patent/CO5140087A1/es unknown
- 2000-02-22 MY MYPI20000647A patent/MY122630A/en unknown
- 2000-02-23 GC GCP2000535 patent/GC0000183A/en active
- 2000-02-23 AR ARP000100756A patent/AR029616A1/es not_active Application Discontinuation
2001
- 2001-08-02 ZA ZA200106371A patent/ZA200106371B/en unknown
- 2001-08-09 IL IL144851A patent/IL144851A/en not_active IP Right Cessation
- 2001-08-23 MA MA26301A patent/MA26773A1/fr unknown
- 2001-08-23 NO NO20014098A patent/NO320099B1/no unknown

Also Published As

Publication number	Publication date
GC0000183A (en)	2006-03-29
AU772446B2 (en)	2004-04-29
DE60015089D1 (de)	2004-11-25
EP1157005A1 (en)	2001-11-28
AR029616A1 (es)	2003-07-10
NZ513370A (en)	2004-02-27
CN1134417C (zh)	2004-01-14
CN1341100A (zh)	2002-03-20
MY122630A (en)	2006-04-29
HK1044942B (zh)	2004-05-28
YU59901A (sh)	2005-07-19
US6225316B1 (en)	2001-05-01
SI1157005T1 (en)	2005-02-28
PL350428A1 (en)	2002-12-16
HUP0200139A3 (en)	2003-01-28
JO2254B1 (en)	2004-10-07
JP4068305B2 (ja)	2008-03-26
WO2000050401A1 (en)	2000-08-31
NO20014098L (no)	2001-08-23
KR20010102347A (ko)	2001-11-15
ATE280158T1 (de)	2004-11-15
IL144851A0 (en)	2002-06-30
HRP20010604A2 (en)	2002-08-31
IL144851A (en)	2006-08-20
DE60015089T2 (de)	2006-02-16
EP1157005B1 (en)	2004-10-20
CO5140087A1 (es)	2002-03-22
CZ20013047A3 (cs)	2002-02-13
ES2230070T3 (es)	2005-05-01
BR0008494A (pt)	2002-02-05
TR200102489T2 (tr)	2002-04-22
DK1157005T3 (da)	2005-02-14
MA26773A1 (fr)	2004-12-20
ZA200106371B (en)	2002-11-04
AU3154900A (en)	2000-09-14
CA2364662A1 (en)	2000-08-31
PT1157005E (pt)	2005-02-28
JP2002537382A (ja)	2002-11-05
KR100437587B1 (ko)	2004-06-30
CA2364662C (en)	2009-10-20
HK1044942A1 (en)	2002-11-08
HUP0200139A2 (en)	2002-06-29
RU2236402C2 (ru)	2004-09-20
NO20014098D0 (no)	2001-08-23

Publication	Publication Date	Title
EP1157005B1 (en)	2004-10-20	3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
EP1035115B1 (en)	2004-09-29	4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
CA2416874C (en)	2011-01-18	4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
RS59901B1 (sr)	2020-03-31	Proizvodnja fosfatnih jedinjenja iz materijala koji sadrže fosfor i najmanje jedno od gvožđa i aluminijuma
AU2001282005A1 (en)	2002-05-02	4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU2006218179B2 (en)	2010-12-23	NK1 antagonists
MXPA01008511A (es)	2002-05-09	Derivados de 3-fenilpiridina y su uso como antagonistas del receptor de la neuroquinina (nk-1)
MXPA00001849A (en)	2002-06-05	4-phenylpyridine derivatives and their use as nk-1 receptor antagonists